Drug Approval | May 04, 2022
Eugia Pharma receives USFDA approval for Bortezomib
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
The tablets are available in 100 mg strength in bottle count sizes of 60
Subscribe To Our Newsletter & Stay Updated
